arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Ensysce Biosciences, Inc.

ENSC
$0.52 ▲ +0.17 (+48.69%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
35 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
11
Health
Poor
Bearish
auto_awesome

Analytical Summary

Ensysce Biosciences, Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.6M
Dividend Yield
Revenue Growth -27.2%
Op. Margin -370.7%
ROIC 827.6%
FCF / Share $-0.51
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$961.00K
↓ -27.2%
Net Income Profit after all expenses
$-3.56M
↓ -82.8%
Operating Margin Operating profit as % of sales
-370.7%
↓ -150.8% 0th
FCF / Share Free cash flow per share
$-0.51
↑ +58.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Financial Health
3
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 35 quarters